3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Interventions
Paclitaxel
24
Bevacizumab
21
Carboplatin
20
liposomal doxorubicin
15
Specimen Handling
14
olaparib
13
Magnetic Resonance Spectroscopy
13
Gemcitabine
10
Topotecan
9
pembrolizumab
8
Biopsy
8
Taxes
7
Immunoglobulin G
6
Disulfides
6
niraparib
5
Doxorubicin
5
mirvetuximab soravtansine
4
cediranib
4
oregovomab
3
Nivolumab
3
Drug Therapy
3
Docetaxel
3
Cyclophosphamide
3
Cisplatin
3
sarilumab
2
rucaparib
2
cemiplimab
2
berzosertib
2
adavosertib
2
Saline Solution
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fallopian Tube Neoplasms
×
Histamine H2 Antagonists
×
90 days
×
Clear all
NCT06824467
2026-05-29
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3
Recruiting
770 enrolled